Inici › Leucèmia bifenotípica aguda › Texas › Houston
Assaigs clínics de Leucèmia bifenotípica aguda a Houston, TX
11 estudis de Leucèmia bifenotípica aguda busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ReclutantFase 1
- University of Texas MD Anderson Cancer Center, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
ReclutantFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
ReclutantFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutantFase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
ReclutantFase 2
- M D Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
ReclutantFase 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
ReclutantFase 1/2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
ReclutantFase 2
- M D Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
ReclutantFase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Assaigs de Leucèmia bifenotípica aguda en altres ciutats
- Seattle, WA15 estudis
- New York City, NY10 estudis
- Atlanta, GA9 estudis
- Durham, NC8 estudis
- Memphis, TN7 estudis
- Chicago, IL7 estudis
- Charlotte, NC6 estudis
- Aurora, CO6 estudis
- Baldwin Park, CA6 estudis
- Portland, OR6 estudis
- Los Angeles, CA6 estudis
- Philadelphia, PA6 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Melanoma59 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.